Patents by Inventor Liangliang BI

Liangliang BI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11542336
    Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: January 3, 2023
    Assignee: GMAX BIOPHARM LLC
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Liangliang Bi, Shuqian Jing
  • Publication number: 20210122827
    Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
    Type: Application
    Filed: March 19, 2019
    Publication date: April 29, 2021
    Applicant: GMAX BIOPHARM LLC
    Inventors: Cheng ZHANG, Hua ZHANG, Xiaofeng WANG, Chenjiang YAO, Yan JIANG, Liangliang BI, Shuqian JING